{
    "info": {
        "nct_id": "NCT05648968",
        "official_title": "A Phase 3, Randomized, Double-blind, Study to Assess Efficacy and Safety of Ianalumab (VAY736) Versus Placebo in Warm Autoimmune Hemolytic Anemia (wAIHA) Patients Who Failed at Least One Line of Treatment",
        "inclusion_criteria": "* 18 years and older at time of signing consent\n* Patients with primary or secondary wAIHA documented by positive direct antiglobulin test specific for anti-IgG or anti-IgA, who had an insufficient response to, or relapsed after at least one line of treatment, including patients with steroid resistance, dependence or intolerance\n* Hemoglobin concentration at screening and at Week 1 >=5 g/dL and <10 g/dL, associated with presence of symptoms related to anemia\n* The dose of supportive care must be stable for at least 4 weeks prior to randomization into the study\n\nKey\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 100 Years",
        "exclusion_criteria": "* wAIHA secondary to hematologic disease involving bone marrow (e.g., CLL) or another immunologic disease requiring prohibited medication as per protocol. Patients with autoimmune diseases after wash-out from the treatments are allowed.\n* Presence of other forms of AIHA (cold or intermediate forms), Evans Syndrome or other cytopenias\n* Prior use of B-cell depleting therapy (e.g., rituximab) within 12 weeks prior to randomization, or without hematological response to the last course of B-cell depleting therapy\n* Neutrophils: <1000/mm3\n* Serum creatinine >1.5 × upper limit of normal (ULN)\n* Immunoglobulin G (IgG) <5g/L\n* Active viral, bacterial or other infections (including tuberculosis and SARS-CoV-2) requiring systemic treatment at time of screening, or history of recurrent clinically significant infection\n* Positivity for hepatitis C virus, hepatitis B surface antigen (HBsAg), or hepatitis B core antibody (HBcAb). HBcAb positive patients can be enrolled if HBsAg negative, HBV DNA negative, no pre-existing liver fibrosis is present and antiviral prophylaxis is given.\n* Known history of primary or secondary immunodeficiency, or a positive human immune deficiency virus (HIV) test result\n* Live or live-attenuated vaccination within 4 weeks before randomization\n* History of splenectomy\n\nOther protocol-defined Inclusion/Exclusion may apply.",
        "miscellaneous_criteria": "Key"
    },
    "inclusion_lines": [
        {
            "line": "Key",
            "criterions": [
                {
                    "exact_snippets": "Key",
                    "criterion": "key status",
                    "requirements": [
                        {
                            "requirement_type": "N/A",
                            "expected_value": "Key"
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* 18 years and older at time of signing consent",
            "criterions": [
                {
                    "exact_snippets": "18 years and older at time of signing consent",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum age",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients with primary or secondary wAIHA documented by positive direct antiglobulin test specific for anti-IgG or anti-IgA, who had an insufficient response to, or relapsed after at least one line of treatment, including patients with steroid resistance, dependence or intolerance",
            "criterions": [
                {
                    "exact_snippets": "primary or secondary wAIHA",
                    "criterion": "wAIHA (warm autoimmune hemolytic anemia)",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "type",
                            "expected_value": [
                                "primary",
                                "secondary"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "documented by positive direct antiglobulin test specific for anti-IgG or anti-IgA",
                    "criterion": "direct antiglobulin test",
                    "requirements": [
                        {
                            "requirement_type": "result",
                            "expected_value": "positive"
                        },
                        {
                            "requirement_type": "specificity",
                            "expected_value": [
                                "anti-IgG",
                                "anti-IgA"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "insufficient response to, or relapsed after at least one line of treatment",
                    "criterion": "response to prior treatment",
                    "requirements": [
                        {
                            "requirement_type": "response",
                            "expected_value": [
                                "insufficient response",
                                "relapsed"
                            ]
                        },
                        {
                            "requirement_type": "number of prior lines of treatment",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "line(s)"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "including patients with steroid resistance, dependence or intolerance",
                    "criterion": "steroid response",
                    "requirements": [
                        {
                            "requirement_type": "response",
                            "expected_value": [
                                "resistance",
                                "dependence",
                                "intolerance"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* The dose of supportive care must be stable for at least 4 weeks prior to randomization into the study",
            "criterions": [
                {
                    "exact_snippets": "The dose of supportive care must be stable for at least 4 weeks prior to randomization into the study",
                    "criterion": "supportive care dose",
                    "requirements": [
                        {
                            "requirement_type": "stability duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Hemoglobin concentration at screening and at Week 1 >=5 g/dL and <10 g/dL, associated with presence of symptoms related to anemia",
            "criterions": [
                {
                    "exact_snippets": "Hemoglobin concentration at screening and at Week 1 >=5 g/dL and <10 g/dL",
                    "criterion": "hemoglobin concentration",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 5,
                                        "unit": "g/dL"
                                    },
                                    {
                                        "operator": "<",
                                        "value": 10,
                                        "unit": "g/dL"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "associated with presence of symptoms related to anemia",
                    "criterion": "symptoms related to anemia",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have maximum age of 100 Years",
            "criterions": [
                {
                    "exact_snippets": "maximum age of 100 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "maximum",
                            "expected_value": {
                                "operator": "<=",
                                "value": 100,
                                "unit": "Years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "* Presence of other forms of AIHA (cold or intermediate forms), Evans Syndrome or other cytopenias",
            "criterions": [
                {
                    "exact_snippets": "Presence of other forms of AIHA (cold or intermediate forms)",
                    "criterion": "other forms of AIHA",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Presence of ... Evans Syndrome",
                    "criterion": "Evans Syndrome",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Presence of ... other cytopenias",
                    "criterion": "other cytopenias",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Neutrophils: <1000/mm3",
            "criterions": [
                {
                    "exact_snippets": "Neutrophils: <1000/mm3",
                    "criterion": "neutrophil count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 1000,
                                "unit": "mm3"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Serum creatinine >1.5 × upper limit of normal (ULN)",
            "criterions": [
                {
                    "exact_snippets": "Serum creatinine >1.5 × upper limit of normal (ULN)",
                    "criterion": "serum creatinine",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 1.5,
                                "unit": "ULN"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of splenectomy",
            "criterions": [
                {
                    "exact_snippets": "History of splenectomy",
                    "criterion": "splenectomy",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Known history of primary or secondary immunodeficiency, or a positive human immune deficiency virus (HIV) test result",
            "criterions": [
                {
                    "exact_snippets": "Known history of primary or secondary immunodeficiency",
                    "criterion": "immunodeficiency",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "a positive human immune deficiency virus (HIV) test result",
                    "criterion": "HIV infection",
                    "requirements": [
                        {
                            "requirement_type": "test result",
                            "expected_value": "positive"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Active viral, bacterial or other infections (including tuberculosis and SARS-CoV-2) requiring systemic treatment at time of screening, or history of recurrent clinically significant infection",
            "criterions": [
                {
                    "exact_snippets": "Active viral, bacterial or other infections (including tuberculosis and SARS-CoV-2) requiring systemic treatment at time of screening",
                    "criterion": "active infection",
                    "requirements": [
                        {
                            "requirement_type": "type",
                            "expected_value": [
                                "viral",
                                "bacterial",
                                "other (including tuberculosis and SARS-CoV-2)"
                            ]
                        },
                        {
                            "requirement_type": "treatment requirement",
                            "expected_value": "requiring systemic treatment"
                        },
                        {
                            "requirement_type": "time",
                            "expected_value": "at time of screening"
                        }
                    ]
                },
                {
                    "exact_snippets": "history of recurrent clinically significant infection",
                    "criterion": "history of recurrent clinically significant infection",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "recurrence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "clinical significance",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Other protocol-defined Inclusion/Exclusion may apply.",
            "criterions": [
                {
                    "exact_snippets": "Other protocol-defined Inclusion/Exclusion may apply.",
                    "criterion": "other protocol-defined inclusion/exclusion criteria",
                    "requirements": [
                        {
                            "requirement_type": "applicability",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* wAIHA secondary to hematologic disease involving bone marrow (e.g., CLL) or another immunologic disease requiring prohibited medication as per protocol. Patients with autoimmune diseases after wash-out from the treatments are allowed.",
            "criterions": [
                {
                    "exact_snippets": "wAIHA secondary to hematologic disease involving bone marrow (e.g., CLL)",
                    "criterion": "wAIHA secondary to hematologic disease involving bone marrow",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "another immunologic disease requiring prohibited medication as per protocol",
                    "criterion": "immunologic disease requiring prohibited medication",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Patients with autoimmune diseases after wash-out from the treatments are allowed",
                    "criterion": "autoimmune diseases after wash-out from the treatments",
                    "requirements": [
                        {
                            "requirement_type": "wash-out from the treatments",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Immunoglobulin G (IgG) <5g/L",
            "criterions": [
                {
                    "exact_snippets": "Immunoglobulin G (IgG) <5g/L",
                    "criterion": "Immunoglobulin G (IgG) level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 5,
                                "unit": "g/L"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Prior use of B-cell depleting therapy (e.g., rituximab) within 12 weeks prior to randomization, or without hematological response to the last course of B-cell depleting therapy",
            "criterions": [
                {
                    "exact_snippets": "Prior use of B-cell depleting therapy (e.g., rituximab) within 12 weeks prior to randomization",
                    "criterion": "B-cell depleting therapy use",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 12,
                                "unit": "weeks"
                            }
                        },
                        {
                            "requirement_type": "temporal_relation",
                            "expected_value": "prior to randomization"
                        }
                    ]
                },
                {
                    "exact_snippets": "without hematological response to the last course of B-cell depleting therapy",
                    "criterion": "hematological response to last course of B-cell depleting therapy",
                    "requirements": [
                        {
                            "requirement_type": "response",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Positivity for hepatitis C virus, hepatitis B surface antigen (HBsAg), or hepatitis B core antibody (HBcAb). HBcAb positive patients can be enrolled if HBsAg negative, HBV DNA negative, no pre-existing liver fibrosis is present and antiviral prophylaxis is given.",
            "criterions": [
                {
                    "exact_snippets": "Positivity for hepatitis C virus",
                    "criterion": "hepatitis C virus infection",
                    "requirements": [
                        {
                            "requirement_type": "positivity",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Positivity for ... hepatitis B surface antigen (HBsAg)",
                    "criterion": "hepatitis B surface antigen (HBsAg)",
                    "requirements": [
                        {
                            "requirement_type": "positivity",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Positivity for ... hepatitis B core antibody (HBcAb)",
                    "criterion": "hepatitis B core antibody (HBcAb)",
                    "requirements": [
                        {
                            "requirement_type": "positivity",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "HBcAb positive patients can be enrolled if HBsAg negative",
                    "criterion": "hepatitis B surface antigen (HBsAg) in HBcAb positive patients",
                    "requirements": [
                        {
                            "requirement_type": "positivity",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "HBcAb positive patients can be enrolled if ... HBV DNA negative",
                    "criterion": "HBV DNA in HBcAb positive patients",
                    "requirements": [
                        {
                            "requirement_type": "positivity",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "HBcAb positive patients can be enrolled if ... no pre-existing liver fibrosis is present",
                    "criterion": "pre-existing liver fibrosis in HBcAb positive patients",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "HBcAb positive patients can be enrolled if ... antiviral prophylaxis is given",
                    "criterion": "antiviral prophylaxis in HBcAb positive patients",
                    "requirements": [
                        {
                            "requirement_type": "administration",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Live or live-attenuated vaccination within 4 weeks before randomization",
            "criterions": [
                {
                    "exact_snippets": "Live or live-attenuated vaccination within 4 weeks before randomization",
                    "criterion": "live or live-attenuated vaccination",
                    "requirements": [
                        {
                            "requirement_type": "timing before randomization",
                            "expected_value": {
                                "operator": "<=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [
        {
            "line": "Key",
            "criterions": [
                {
                    "exact_snippets": "Key",
                    "criterion": "key status",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        }
    ],
    "failed_inclusion": [],
    "failed_exclusion": [],
    "failed_miscellaneous": []
}